Fintel reports that on August 22, 2023, Cantor Fitzgerald downgraded their outlook for Aravive (NASDAQ:ARAV) from Overweight to Neutral.
Analyst Price Forecast Suggests 5,995.12% Upside
As of August 2, 2023, the average one-year price target for Aravive is 12.50. The forecasts range from a low of 9.09 to a high of $18.90. The average price target represents an increase of 5,995.12% from its latest reported closing price of 0.20.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Aravive is 1MM, a decrease of 85.56%. The projected annual non-GAAP EPS is -1.37.
What is the Fund Sentiment?
There are 63 funds or institutions reporting positions in Aravive. This is an increase of 6 owner(s) or 10.53% in the last quarter. Average portfolio weight of all funds dedicated to ARAV is 0.03%, a decrease of 32.69%. Total shares owned by institutions increased in the last three months by 5.08% to 17,221K shares. The put/call ratio of ARAV is 0.89, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 4,784K shares representing 7.99% ownership of the company. No change in the last quarter.
Artal Group holds 4,573K shares representing 7.64% ownership of the company. No change in the last quarter.
Baker Bros. Advisors holds 3,261K shares representing 5.45% ownership of the company. No change in the last quarter.
VTSMX – Vanguard Total Stock Market Index Fund Investor Shares holds 2,189K shares representing 3.66% ownership of the company. In it’s prior filing, the firm reported owning 257K shares, representing an increase of 88.26%. The firm increased its portfolio allocation in ARAV by 1,091.56% over the last quarter.
New Leaf Venture Partners, L.L.C. holds 946K shares representing 1.58% ownership of the company. No change in the last quarter.
Aravive Background Information
(This description is provided by the company.)
Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Aravive’s lead product candidate, AVB-500, is an ultra-high affinity decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth. Aravive successfully completed a Phase 1b trial of AVB-500 in platinum resistant ovarian cancer and has initiated a registrational Phase 3 trial of AVB-500 at a dose of 15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant ovarian cancer was a safety trial and not powered to demonstrate efficacy, all 5 patients in the 15 mg/kg cohort experienced clinical benefit, with 1 complete response, 2 partial responses, and 2 stable disease. The Company is dosing patients in its Phase 1b/2 trial in clear cell renal cell carcinoma.
This article originally appeared on Fintel
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
